IMMUNIC, INC.
Immunic, Inc. (NASDAQ: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company maintains headquarters in New York City with primary operations in Gräfelfing near Munich, Germany, and additional research facilities in… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What IMMUNIC, INC. does
In the company’s own words
Immunic, Inc. (NASDAQ: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company maintains headquarters in New York City with primary operations in Gräfelfing near Munich, Germany, and additional research facilities in Melbourne, Australia, Martinsried, and Halle/Saale, Germany. As of February 2026, Immunic employs 92 people across its global operations.
The company's pipeline consists of three primary product candidates. Vidofludimus calcium (IMU-838), the most advanced program, is in Phase 3 clinical development for relapsing multiple sclerosis through the ENSURE program, which completed enrollment of over 2,200 patients across 15 countries. The compound has demonstrated therapeutic activity in Phase 2 trials for relapsing-remitting and progressive multiple sclerosis. IMU-856 targets intestinal barrier function restoration through Sirtuin 6 modulation and is being developed for gastrointestinal diseases including celiac disease, inflammatory bowel disease, and graft-versus-host disease. Phase 1b data showed positive effects on gut architecture, symptom improvement, and biomarker response. IMU-381 comprises next-generation molecules in preclinical testing leveraging the company's Nurr1 platform for neurologic and gastrointestinal applications.
Immunic's therapeutic approach centers on small molecule inhibitors with dual mechanisms of action. Vidofludimus calcium functions as a selective dihydroorotate dehydrogenase inhibitor with neuroprotective properties through Nurr1 activation, providing combined anti-inflammatory, antiviral, and neuroprotective effects. The company has exposed over 3,400 human subjects to vidofludimus calcium across its formulations.
The company has never generated product revenue and maintains an accumulated deficit of approximately $608.6 million as of December 31, 2025. Immunic has raised approximately $496.3 million from inception through equity offerings and secured $187 million in net proceeds from a February 2026 private placement. The company operates through its wholly-owned German subsidiary Immunic AG and maintains a subsidiary, Gliomic Therapeutics Inc., pursuing brain cancer applications. Immunic's intellectual property includes a patent covering vidofludimus calcium dose strengths for progressive multiple sclerosis treatment extending to 2041.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, X1
- Fiscal year end
- December
- CIK
- 1280776
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns IMMUNIC, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · IMMUNIC, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do IMMUNIC, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of IMMUNIC, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in IMMUNIC, INC.'s last four quarterly filings that the numbers alone won't show?”